|Location||Austria - Vienna|
|Start Date||Mar 10, 2020|
|End Date||May 11, 2020|
|Event Type||Grant & Award|
|Subject Area||Nanomedicine - Pharmaceutics Biology - Life science|
The Call is aimed at Austrian companies planning a research and development project according to the Call Guideline KLIPHA-COVID19.
Companies submitting clinical trials must have preliminary results or experience with using the substance to be tested on other coronaviruses (e.g. SARS, MERS) or must have products on the market which have already demonstrated to be effective against coronaviruses in general or against symptoms similar to those caused by the SARS-CoV-2 virus (e.g. respiratory diseases).
- Virus biology and transmission;
- Infection prevention and control;
- Research and development of medicines and other treatments and development of new diagnostic methods;
- Planning and conduct of clinical trials